Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The association of some cases of endometrial carcinoma (EC) with hyperestrogenism is well known. The prognostic significance of concomitant endometrial hyperplasia (EH) in EC were evaluated in 142 patients with clinical stage I EC in whom lymph node assessment was carried out in 121 patients. The presence of EH was significantly associated with better differentiated tumor having lesser degrees of myometrial invasion, low segment-adnexal-lymphovascular space and pelvic/para-aortic lymph node involvement. However, the presence of EH was not significantly associated with the less virulent histologic subtypes. The possible existence of two types of EC--a hormonal-dependent EC associated with EH, and an independent EC not associated with EH--is discussed and the prognostic significance of concomitant EH stressed.
 ...
PMID:Endometrial carcinoma: a pathologic evaluation of 142 cases with and without associated endometrial hyperplasia. 201 Oct 30

It is widely recognized that endometrial carcinoma represents one of the most frequent types of pelvic malignancy in women. Recent improved knowledge about population at risk, the criteria of classification of endometrial hyperplasia, different potential for neoplastic transformation for each type of neoplasia, and asymptomatic latency of the pathology allow some considerations. Endometrial cytology is of basic importance in a mass screening programme due to its low cost, accuracy and feasibility. The combination of hysteroscopy and endometrial biopsy is the diagnostic method of choice for symptomatic patients. It permits the elimination of curettage in the diagnostic management in over 95% of cases, with obvious advantages, better diagnostic accuracy and greater convenience for patients and doctors.
 ...
PMID:Early detection of endometrial cancer and hyperplasia: a reappraisal. 205 51

In summary, endometrial cancer is an estrogen-related neoplasm whose precursor lesion, endometrial hyperplasia, may be successfully treated with progestational agents. Trials of adjunctive progestin therapy have failed to demonstrate benefit, even though the malignancy is sensitive to palliative therapy with progestins as well as tamoxifen. Paradoxically, chronic tamoxifen exposure in postmenopausal women may increase the risk of endometrial cancer, and such women must be followed closely. Progesterone receptor may be measured using competitive binding assays or by immunohistochemical techniques. There is tumor heterogeneity with regard to progesterone receptor. Tissues surrounding the cancer may contain progesterone receptor and produce false-positive results in biochemical assays. Last, the presence of progesterone receptor not only predicts responsiveness to progestational therapy, but also confers a survival advantage in patients with endometrial cancer.
 ...
PMID:Hormonal aspects of endometrial cancer. 210 9

The amount and distribution of carcinoembryonic antigen (CEA) was determined in 41 cases of endometrial carcinoma and 23 cases of endometrial hyperplasia using the Avidin-biotin-peroxidase-complex technique. The surface location and amount of CEA in cancer specimens were found to be related to the histological differentiation of tumor. In endometrial hyperplasia, the content of CEA was the same as that of cancer, but the surface location was different.
 ...
PMID:[Detection of carcinoembryonic antigen of endometrial carcinoma and hyperplasia]. 218 9

Endometrial cancer is currently the commonest pelvic malignancy affecting American women, most of whom share the same pathophysiologic basis, that is, unopposed estrogenic stimulation. The initial result of hyperestrogenism is the development of endometrial hyperplasia, which is reversible in most cases by appropriate hormonal therapy. Persistent stimulation eventually leads to atypical hyperplasia with nuclear atypia and invasive carcinoma. Because there is no cost-effective screening method for the detection of endometrial hyperplasia and carcinoma, it is essential to survey the high-risk population with appropriate diagnostic techniques. After diagnosis, therapy should be individualized based on pathologic findings (cell type and histologic grade) and extent of disease (International Federation of Gynaecologists and Obstetricians stage, depth of myometrial invasion, and pelvic and para-aortic lymph node status). Recent studies suggest that sex hormone receptors and nuclear DNA ploidy patterns provide useful prognostic information independent of histologic grade.
 ...
PMID:Pathophysiology and management of endometrial hyperplasia and carcinoma. 238 79

Clinical classification of gynecological tumours according to UICC and FIGO, and their histological classification according to WHO and the Japanese general rules for clinical and pathological management of gynecological tumours are presented. We have discussed the following histological topics which have close correlation with the clinical staging of gynecological tumours. 1. Postoperative recording of definite diagnosis according to pTNM and FIGO. 2. Difference of diagnostic criteria between squamous cell and adenocarcinoma of Ia stage of cervical cancer. 3. Differential diagnosis of atypical endometrial hyperplasia and carcinoma in situ in endometrial cancer. 4. Objective findings for corporeal cavity and myometrial invasion of corpus carcinoma. 5. Correlation between histological classification of ovarian tumours and their malignant potentials. 6. Clinical significance of histological diagnosis of ovarian tumours invasion and cytological diagnosis of ascitic fluids.
 ...
PMID:[Histological and clinical classification of gynecological tumours]. 221 45

The altered expression of the human retinoblastoma (RB) gene has been demonstrated to play an important role in the pathogenesis of RB and other tumors. To determine whether the RB gene might be involved in the pathogenesis of human ovarian and endometrial cancer, DNA from 24 human ovarian tumors, 3 normal ovaries, 3 endometrial carcinomas, and 1 endometrial hyperplasia was examined with an RB complementary DNA probe. Evidence for homozygous deletion of the RB gene was observed in only one specimen. Interestingly, the specimen was an endometrioid tumor of the ovary of low malignant potential (LMP). This patient experienced rapid progression of the tumor and died 8 months after diagnosis. Abnormalities of the RB gene may be involved in the aggressive biologic behavior of certain forms of ovarian carcinoma, particularly those of LMP.
 ...
PMID:An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. 222 70

In a series of 52 biopsy specimens (31 endometrial carcinomas, 10 atypical endometrial hyperplasias, and 11 cases of normal endometrium), DNA ploidy and S-phase cell fraction were estimated in paraffin-embedded material. DNA aneuploidy was detected in 2 of the 10 atypical endometrial hyperplasias and 7 of the 31 endometrial carcinomas. The majority of aneuploidy was found to be connected with the loss of tumor differentiation. No ploidy disturbances were found in normal endometrium. The S-phase cell fraction value of normal endometrium was significantly lower when compared with that of endometrial carcinoma. The broad variation in S-phase cell fraction values of the endometrial carcinomas and atypical endometrial hyperplasias was in contrast with the low variability of S-phase cell values of normal endometrium. Very low incidence of aneuploidy in the group of well differentiated endometrial carcinomas (Grade I) enables the suggestion that the presence of aneuploidy predicts a more aggressive disease and that the detection of an aneuploid stemline in atypical endometrial hyperplasia may already indicate the neoplastic transformation.
 ...
PMID:Flow cytometry (FCM) analysis of endometrial hyperplasia and carcinoma. 223 10

One hundred eighty-eight women who had endometrial cells on cervical cytologic specimens during the secretory phase or in the postmenopausal period were studied retrospectively. Each had undergone hysterectomy or endometrial biopsy within 12 months of the original smear. The endometrial cells were classified as typical, atypical, or suspicious for carcinoma. Among premenopausal subjects, three of 57 with typical cells had endometrial hyperplasia, one of two with atypical cells had endometrial polyps, and both with cells suspicious for carcinoma had endometrial carcinoma. In the postmenopausal group, ten (13.5%) of 74 with typical endometrial cells had either hyperplasia or carcinoma, and five (22.7%) of 22 with atypical cells and 24 77.4%) of 31 patients with suspicious cells had either hyperplasia or carcinoma. The present findings and a review of the pertinent literature demonstrate that the classification system used is helpful in predicting the risk for endometrial disease in patients with endometrial cells seen on cervical cytologic smears during the secretory phase or in the postmenopausal period.
 ...
PMID:Classification of endometrial cells on cervical cytology. 223 6

An analysis of clinical and family history of 36 patients with endometrial cancer revealed clustering of tumors in some families. Cytogenetic studies of peripheral lymphocytes showed increased counts of aberrant cells in patients with endometrial cancer as against their values in normal women and patients with endometrial hyperplasia.
 ...
PMID:[Use of genetic analysis methods in examining patients with endometrial cancer]. 233 63


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>